Summary
Migraine Market Research Report Information by Type (Episodic and Chronic), By Treatment Type (Preventive, Abortive), By Drug Class (Triptans, Ergots, and Others), And by Region (North America, Europe, Asia-Pacific, And Rest Of The World) Market Forecast Till 2032
Market Overview
In 2023, the migraine market was estimated at USD 5.68 billion. The global migraine industry is expected to expand from USD 6.00 billion in 2024 to USD 8.42 billion by 2032, with a compound annual growth rate (CAGR) of 3.83% over the forecast period (2024-2032).
Growing public awareness of innovative medication classes, as well as an increase in migraine disorders worldwide, are significant market drivers boosting growth.
Two factors influencing the target market's growth are an increase in migraine cases worldwide and increased public awareness of novel treatment classes. The introduction of calcitonin gene-related peptide (CGRP) is also expected to help this business grow. A migraine is a persistent, severe headache accompanied by nausea, phonophobia, and photophobia. The condition develops in part due to genetics. Emotions out of balance, such as sadness, stress, concern, shock, and exhilaration, can cause migraine headaches. Each migraine episode varies in duration and severity, with most affecting only one side of the head. An increase in the prevalence of migraines with major unmet needs, increased R&D spending resulting in a huge pipeline of drugs, and rising awareness of migraine and treatment choices are all contributing causes.
Market Segment insights
Migraine market segments include episodic and chronic.
Migraine Market segmentation is based on therapy type, which includes preventive and abortive.
Surgery has divided the Market statistics into Triptans, Ergots, and Others.
Migraine Regional Insights
The study covers North America, Europe, Asia-Pacific, and the rest of the world. The Asia Pacific Migraine market is predicted to develop at a considerable CAGR over the study period. The Asia Pacific acute migraine treatment market is predicted to grow due to increased healthcare costs and improved infrastructure in developing countries such as China and India. Another major element that is going to accelerate the regional market is the ease of access to economical migraine treatment choices, which is being backed by expanding regulatory body activities. By the India Brand Equity Foundation.
Europe's migraine market has the second-largest market share. The target market's growth is influenced by two factors: growing public knowledge of novel medication classes and a global increase in migraines. Furthermore, the introduction of calcitonin gene-related peptide (CGRP) is expected to accelerate the industry's growth.
The North American Migraine Market is predicted to expand at the quickest CAGR between 2024 and 2032. Growing investment from key parties based in the United States. According to estimates, considerable research and development activities in the United States, Canada, and other nations to discover novel treatment choices will boost the domestic market. The American Family Physician estimates that there are around 441.5 million adults in the United States, with 6 to 9 percent men and 18 to 26 percent women. The United States endured a migraine in 2009.
Major Players
Major competitors in the migraine industry include Sanofi SA, Abbott Laboratories, Teva Pharmaceutical Industries Limited, Allergan Plc, Pfizer Inc, AstraZeneca, Johnson & Johnson, Endo International Plc, GlaxoSmithKline Plc, Impax Laboratories, and others.
ページTOPに戻る
Table of Contents
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY ................................................................................ 21
2 MARKET INTRODUCTION ...................................................................... 23
2.1 DEFINITION ..................................................................................................................... 23
2.2 SCOPE OF THE STUDY ................................................................................................ 23
2.3 RESEARCH OBJECTIVE .......................................................................................................... 23
2.4 MARKET STRUCTURE ............................................................................................................. 24
3 RESEARCH METHODOLOGY .......................................................... 25
3.1 OVERVIEW ............................................................................................. 25
3.2 DATA FLOW ................................................................................................................................. 26
3.2.1 DATA MINING PROCESS............................................................................................ 27
3.3 PURCHASED DATABASE: ......................................................................................................... 29
3.4 SECONDARY SOURCES: ......................................................................................................... 30
3.4.1 SECONDARY RESEARCH DATA FLOW: ............................................................................................................. 32
3.5 PRIMARY RESEARCH:............................................................................................... 33
3.5.1 PRIMARY RESEARCH DATA FLOW: ................................................................................................................. 34
3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED ......................................................................... 35
3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE .......................................................... 35
3.6 APPROACHES FOR MARKET SIZE ESTIMATION: ............................................... 36
3.6.1 REVENUE ANALYSIS APPROACH ......................................................................... 36
3.7 DATA FORECASTING........................................................................................................... 37
3.7.1 DATA FORECASTING TECHNIQUE ......................................................................... 37
3.8 DATA MODELING ............................................................................................. 38
3.8.1 MICROECONOMIC FACTOR ANALYSIS: ....................................................................... 38
3.8.2 DATA MODELING: .................................................................................................... 39
3.9 TEAMS AND ANALYST CONTRIBUTION ........................................................... 41
4 MARKET DYNAMICS .............................................................................. 43
4.1 DRIVERS ............................................................................................................................... 44
4.1.1 INCREASING INCIDENCES/PREVALENCE OF MIGRAINE .......................................................... 44
4.1.2 RISING APPROVAL FOR THERAPEUTIC MIGRAINE PRODUCTS .......................................... 44
4.2 RESTRAINTS .............................................................................................................. 46
4.2.1 VOLUNTARY PRODUCT RECALL BY MARKET PLAYERS ....................................................... 46
4.3 OPPORTUNITY ............................................................................................................... 47
4.3.1 ONGOING CLINICAL TRIALS ASSOCIATED WITH MIGRAINE EFFICACY AND SAFETY .................. 47
4.4 PORTER'S FIVE FORCES MODEL ............................................................................. 49
4.4.1 THREAT OF NEW ENTRANTS .......................................................................................... 49
4.4.2 BARGAINING POWER OF SUPPLIERS ..................................................................... 49
4.4.3 THREAT OF SUBSTITUTES ......................................................................................... 50
4.4.4 BARGAINING POWER OF BUYERS ................................................................................. 50
4.4.5 INTENSITY OF RIVALRY ................................................................................................ 50
4.5 IMPACT OF COVID-19 ON GLOBAL MIGRAINE MARKET ......................................... 50
5 GLOBAL MIGRAINE MARKET, BY MIGRAINE TYPE .................................... 53
5.1 OVERVIEW ........................................................................................................ 53
5.2 MIGRAINE WITH AURA ........................................................................................ 55
5.3 MIGRAINE WITHOUT AURA ........................................................................................... 55
5.4 OTHERS ................................................................................................................. 56
6 GLOBAL MIGRAINE MARKET, BY TREATMENT ............................................ 57
6.1 OVERVIEW ......................................................................................................................... 57
6.2 MEDICATION ........................................................................................................ 60
6.2.1 CGRP INHIBITORS .......................................................................................................... 61
6.2.1.1 RIMEGEPANT ........................................................................................................ 61
6.2.1.2 UBROGEPANT ................................................................................................. 62
6.2.1.3 OTHERS ....................................................................................................................... 62
6.2.2 TRIPTANS ..................................................................................................................... 63
6.2.2.1 SUMATRIPTAN SUCCINATE ........................................................................................ 63
6.2.2.2 ZOLMITRIPTAN .......................................................................................................... 64
6.2.2.3 RIZATRIPTAN ........................................................................................................ 64
6.2.2.4 OTHERS ......................................................................................................... 65
6.2.3 ERGOTS ................................................................................................................. 65
6.2.3.1 DIHYDROERGOTAMINE .................................................................................................. 66
6.2.3.2 ERGOTAMINE TARTRATE ................................................................................... 66
6.2.3.3 OTHERS .......................................................................................................... 67
6.2.4 ACETYLCHOLINE INHIBITORS/ NEUROTOXINS ............................................................... 67
6.2.5 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) ................................................... 68
6.2.6 BETA-BLOCKERS .............................................................................................................. 68
6.2.7 CALCIUM CHANNEL BLOCKERS ........................................................................................ 69
6.2.8 DITANS ...................................................................................................................... 69
6.2.9 OTHERS .................................................................................................................. 70
6.3 DEVICE-BASED THERAPIES .................................................................. 70
6.3.1 ELECTRICAL NEUROMODULATION DEVICE ............................................................ 71
6.3.2 TRANSCRANIAL MAGNETIC STIMULATION DEVICE .........................................................72
6.3.3 VAGUS NERVE STIMULATION DEVICE .................................................................72
6.3.4 OTHERS ......................................................................................................... 73
7 GLOBAL MIGRAINE MARKET, BY DISTRIBUTION CHANNEL ........................ 74
7.1 OVERVIEW ............................................................................................................................ 74
7.2 ONLINE ............................................................................................................. 75
7.3 OFFLINE ............................................................................................................................ 76
8 GLOBAL MIGRAINE MARKET, BY REGION .................................................... 77
8.1 OVERVIEW .............................................................................................................................. 77
8.2 NORTH AMERICA ....................................................................................................................... 78
8.2.1 US........................................................................................................................................ 83
8.2.2 CANADA ................................................................................................................................... 86
8.3 EUROPE ....................................................................................................................... 90
8.3.1 GERMANY ........................................................................................................................... 95
8.3.2 FRANCE .................................................................................................................................. 98
8.3.3 UK .................................................................................................................................. 101
8.3.4 ITALY ..................................................................................................................... 104
8.3.5 SPAIN ..................................................................................................................... 108
8.3.6 REST OF EUROPE .................................................................................................................. 112
8.4 ASIA-PACIFIC ...................................................................................................................... 116
8.4.1 CHINA ................................................................................................................... 122
8.4.2 INDIA ................................................................................................................................. 125
8.4.3 JAPAN ........................................................................................................................... 128
8.4.4 SOUTH KOREA ................................................................................................................. 131
8.4.5 AUSTRALIA ........................................................................................................................... 135
8.4.6 NEW ZEALAND ........................................................................................................139
8.4.7 REST OF ASIA-PACIFIC .......................................................................................................... 143
8.5 REST OF THE WORLD ............................................................................................................. 147
8.5.1 MIDDLE EAST ............................................................................................................... 152
8.5.2 LATIN AMERICA ........................................................................................................................ 155
8.5.3 AFRICA ........................................................................................................................... 158
9 COMPETITIVE LANDSCAPE ...................................................................... 163
9.1 INTRODUCTION ...............................................................
9.2 MARKET SHARE ANALYSIS, 2023 ......................................................................... 163
9.3 COMPETITOR DASHBOARD................................................................................................................164
9.4 PUBLIC PLAYERS STOCK SUMMARY ...................................................................................165
9.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL ..................................................... 165
9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES ........................................................... 166
9.6.1 PRODUCT LAUNCH ...................................................................................................... 166
9.6.2 AGREEMENT .............................................................................................................. 166
9.6.3 PRODUCT APPROVAL ........................................................................................ 167
9.6.4 COLLABORATION ................................................................................................................. 168
9.6.5 PRODUCT EXPANSION ............................................................................................................ 168
10 COMPANY PROFILES ..................................................................................... 169
10.1 AMGEN INC............................................................................................................................. 169
10.1.1 COMPANY OVERVIEW ....................................................................................................... 169
10.1.2 FINANCIAL OVERVIEW ....................................................................................................... 170
10.1.3 PRODUCTS OFFERED ........................................................................................................... 171
10.1.4 KEY DEVELOPMENTS ....................................................................................................... 171
10.1.5 SWOT ANALYSIS ................................................................................................................ 171
10.1.6 KEY STRATEGIES ................................................................................................................. 172
10.2 ELI LILLY AND COMPANY .................................................................................................. 173
10.2.1 COMPANY OVERVIEW ................................................................................................... 173
10.2.2 FINANCIAL OVERVIEW ..................................................................................................174
10.2.3 PRODUCTS OFFERED ............................................................................................................174
10.2.4 KEY DEVELOPMENTS ................................................................................................................... 175
10.2.5 SWOT ANALYSIS ................................................................................................................. 176
10.2.6 KEY STRATEGIES ............................................................................................................... 176
10.3 ABBVIE INC. ................................................................................................................................. 177
10.3.1 COMPANY OVERVIEW .......................................................................................................... 177
10.3.2 FINANCIAL OVERVIEW .............................................................................................. 178
10.3.3 PRODUCTS OFFERED ..................................................................................................178
10.3.4 KEY DEVELOPMENTS .................................................................................................179
10.3.5 KEY STRATEGIES ............................................................................................................ 179
10.4 BAUSCH HEALTH COMPANIES INC. ................................................................................ 181
10.4.1 COMPANY OVERVIEW ............................................................................................... 181
10.4.2 FINANCIAL OVERVIEW ....................................................................................................... 182
10.4.3 PRODUCTS OFFERED ..................................................................................................... 182
10.4.4 KEY DEVELOPMENTS ............................................................................................... 182
10.4.5 KEY STRATEGIES ............................................................................................183
10.5 GSK PLC ................................................................................................................................... 184
10.5.1 COMPANY OVERVIEW .............................................................................................................184
10.5.2 FINANCIAL OVERVIEW ............................................................................................. 185
10.5.3 PRODUCT OFFERED ............................................................................................. 186
10.5.4 KEY DEVELOPMENTS .................................................................................................. 186
10.5.5 SWOT ANALYSIS ......................................................................................................... 186
10.5.6 KEY STRATEGIES ............................................................................................................ 187
10.6 TEVA PHARMACEUTICAL INDUSTRIES LTD. ............................................................. 188
10.6.1 COMPANY OVERVIEW ............................................................................................. 188
10.6.2 FINANCIAL OVERVIEW ................................................................................................... 189
10.6.3 PRODUCTS OFFERED ........................................................................................................ 190
10.6.4 KEY DEVELOPMENTS ....................................................................................................... 190
10.6.5 SWOT ANALYSIS .............................................................................................................. 191
10.6.6 KEY STRATEGIES .................................................................................................... 191
10.7 PFIZER INC. ........................................................................................................................ 192
10.7.1 COMPANY OVERVIEW ....................................................................................................... 192
10.7.2 FINANCIAL OVERVIEW .......................................................................................................... 193
10.7.3 PRODUCTS OFFERED .......................................................................................................... 193
10.7.4 KEY DEVELOPMENTS ............................................................................................................... 194
10.7.5 KEY STRATEGIES ................................................................................................................. 194
10.8 THERANICA BIO-ELECTRONICS LTD....................................................................................... 195
10.8.1 COMPANY OVERVIEW .......................................................................................................... 195
10.8.2 FINANCIAL OVERVIEW ............................................................................................................... 196
10.8.3 PRODUCTS OFFERED ..................................................................................................................196
10.8.4 KEY DEVELOPMENTS ................................................................................................................ 196
10.8.5 KEY STRATEGIES ........................................................................................................................ 196
10.9 CEFALY ..................................................................................................................................................... 197
10.9.1 COMPANY OVERVIEW ................................................................................................................... 197
10.9.2 FINANCIAL OVERVIEW .................................................................................................................................... 197
10.9.3 PRODUCTS OFFERED ...................................................................................................................................... 197
10.9.4 KEY DEVELOPMENTS ...................................................................................................................................... 197
10.9.5 KEY STRATEGIES ............................................................................................................................................ 197
10.10 ASTRAZENECA................................................................................................................. 199
10.10.1 COMPANY OVERVIEW ..................................................................................................................................... 199
10.10.2 FINANCIAL OVERVIEW .................................................................................................................................... 200
10.10.3 PRODUCTS OFFERED ...................................................................................................................................... 201
10.10.4 KEY DEVELOPMENTS ...................................................................................................................................... 201
10.10.5 SWOT ANALYSIS ............................................................................................................................................ 201
10.10.6 KEY STRATEGIES ............................................................................................................................................ 202
10.11 DATA CITATIONS .......................................................................................................... 204
